Unique, practical knowledge for nurses responsible for daily management of patients with cardiovascular disease, diabetes and related conditions.

Friday, 21 October 2016

The large randomised controlled trial PARADIGM-HF showed that treatment with sacubitril/valsartan (Entresto) compared with enalapril reduced the risk of hospitalisation, cardiovascular and all-cause mortality and improved symptoms in patients with heart failure with reduced ejection fraction. This article describes the key results and how they can be applied in primary care.

Category: Editorial
Topics covered:
Friday, 21 October 2016

This article gives an overview of sacubitril/valsartan (Entresto), a first-in-class angiotensin receptor-neprilysin inhibitor comprising valsartan, an angiotensin II receptor blocker and the neprilysin inhibitor sacubitril. The drug has been approved for the treatment of symptomatic (NYHA class (II-IV) chronic heart failure and reduced ejection fraction (HF-REF) in adults.

Category: Editorial
Topics covered:
Friday, 21 October 2016

The mechanisms underlying HF are complex and involve the interaction of many hormonal and molecular signalling pathways. These pathways form the basis of many pharmacological treatments, old and new. This article will examine the factors associated with the development of HF, the pathophysiology behind it and the neurohormonal pathways involved in established HF.

Category: Editorial
Topics covered:
Friday, 21 October 2016

This useful Back to Basics poster describes the damaging changes that take place in three key body systems when HF with reduced ejection fraction is left untreated. The sympathetic nervous system, the renin-angiotensin-aldosterone system and the natriuretic peptide system all undergo significant pathophysiological changes as HF progresses.

Category: Back to Basics
Topics covered:
Friday, 21 October 2016

The UK faces an epidemic of heart failure (HF). NICE guidelines emphasise the importance of multidisciplinary assessment and care by HF specialists, evidence-based prescribing, and careful discharge planning after hospitalisation. This article highlights areas where improvements can be made in the management of HF including taking lessons from the latest National Heart Failure Audit.

Category: Editorial
Topics covered:
Friday, 21 October 2016

HF has a major impact on patients, their families, the NHS and social care services. It still has a poor prognosis, worse than many of the common cancers that also affect older people. It causes significant morbidity and imposes a major cost burden on the health service. This editorial provides an introduction to a special supplement on a first-in-class oral treatment for heart failure.

Category: Editorial
Topics covered:
Thursday, 20 October 2016

This month’s Back to Basics feature is a wallchart to support this year’s seasonal flu vaccination programme.

More details can be found at https://www.gov.uk/government/collections/annual-flu-programme

Category: Back to Basics
Topics covered:
Monday, 12 September 2016

Chronic Obstructive Pulmonary Disease (COPD) has a major impact on the health and quality of life of patients and there is often co-morbidity with cardiovascular disease. Well planned and structured training for the primary care team could have a major impact on outcomes.

Category: Editorial
Monday, 12 September 2016
The ‘Year of Care’ is a systematic approach to managing long-term conditions, focused on personalised care planning where patients work with the clinician to agree goals, identify support needs, develop and implement action plans, and monitor progress. This article reports the learning from implementing ‘Year of Care’ in primary care practices in Leeds.
Category: Editorial
Thursday, 08 September 2016

Intensified and multifaceted treatment of patients with type 2 diabetes and poor prognosis due to microalbuminuria extends median lifetime by 8 years compared with conventional therapy, according to a new long-term Danish follow-up study of the Steno-2 trial.

Topics covered:

Article search and filter